Department of Neurology

# CGRP Antibody Therapy and Cerebral Hemodynamics (CATCH)

*Study Summary for Patients*

## Contact Information


| | |
|---|---|
| Study Coordinator: | Sarah Carter<br>Mobile: (813) 541-1909<br>Office: (215) 614-0331<br>Sarah.carter@pennmedicine.upenn.edu |
| Principal Investigator: | Christopher Favilla, MD<br>Mobile: (215) 301-9736<br>Office: (215) 615-3727<br>Christopher.favilla@pennmedicine.upenn.edu |


## Brief Summary of the Research Study

What: This research study is being conducted to study how anti-CGRP medication may impact blood flow in your brain.

Why: Your new medication works by blocking a protein called calcitonin gene-related peptide, or CGRP. CGRP is released by specialized brain cells to make blood vessels open up, which may be important for regulating blood flow in the brain. We will be looking at how well your blood vessels are able to open up before and after you start your medication.

When: If you agree to join the study, you will be asked to attend two research visits. If possible, we will coordinate your first study visit today, while you are already here in clinic. The second research visit will take place when you come back to the clinic to see your Headache Neurology provider. Each visit will last for about 45 minutes.

How: We will look at how your anti-CGRP medication will affect blood flow in your brain by measuring your blood pressure and blood flow at the same time. This involves non-invasive measurements only, and there is no risk involved.

A finger cuff will be used to collect blood pressure data for the entirety of the study. A type of ultrasound, called a Doppler, will measure how fast your blood flow is in 2 of the vessels in your brain. For each vessel, you will breathe in a mixture of 5% $CO_2$ gas for 2 minutes, so we can see how your blood vessels react. This gas mixture is safe and is used commonly in research.

**If you are interested, the study coordinator will go over everything in more detail with you today.**